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Background
Poor physical health in severe mental illness (SMI) remains a
major issue for clinical practice.
Aims
To use electronic health records of routinely collected clinical
data to determine levels of screening for cardiometabolic dis-
ease and adverse health outcomes in a large sample (n = 7718) of
patients with SMI, predominantly schizophrenia and bipolar
disorder.
Method
We linked data from the Glasgow Psychosis Clinical Information
System (PsyCIS) to morbidity records, routine blood results and
prescribing data.
Results
There was no record of routine blood monitoring during the
preceding 2 years for 16.9% of the cohort. However, monitoring
was poorer for male patients, younger patients aged 16–44,
those with schizophrenia, and for tests of cholesterol, triglycer-
ide and glycosylated haemoglobin. We estimated that 8.0% of
participants had diabetes and that lipids levels, and use of lipid-
lowering medication, was generally high.
Conclusions
Electronic record linkage identified poor health screening and
adverse health outcomes in this vulnerable patient group. This
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Background
The physical health of people with severe mental illness (SMI) con-
tinues to be a major public health concern.1 The standardised mortal-
ity rate for individuals with schizophrenia and bipolar disorder is twice
that of the general population.2 The life expectancy of individuals with
SMI is 18.7 years shorter formen and 16.3 years for women,3 with car-
diovascular disease the leading cause of death.4 Despite a consistent
fall in premature mortality within the general population during
recent decades5 the widening differential gap in mortality suggests
that people with schizophrenia and bipolar disorder have not shared
in the improvements in health seen in the population at large.2
It is well documented that individuals with schizophrenia have
high levels of cardiovascular disease,6 metabolic disease,7 diabetes7
and respiratory illness.8 Explanations for the high levels of morbid-
ity are complex and multifactorial including a genetic predispos-
ition, medication effects, environmental factors with high levels of
smoking,6 obesity9 and sedentariness10 all contributing to poor
physical health within this population.
Screening for disorders such as diabetes, cardiovascular disease
and the risk factors associated with these conditions is known to be
suboptimal within this population. Barnes et al11 conducted an
audit of screening for metabolic syndrome in UKmental health ser-
vices in 2006. They found that within the previous year a blood
glucose (or haemoglobin A1c (HbA1c)) had been checked in only
28.0% of individuals, plasma lipids in 22.0% and in 6.0% a docu-
mented diagnosis of diabetes. In the National Audit of
Schizophrenia, Crawford et al12 found that at the time point of
assessment (2011) 59.8% of patients had a plasma glucose recorded,
54.1% had a plasma cholesterol level recorded and 64.6% a blood
pressure recording within the last 12 months.
Existing guidelines on screening individuals with SMI
The National Institute for Health and Care Excellence13 have
recommended that for people with schizophrenia a fasting blood
glucose, HbA1c and blood lipid levels should be measured at inter-
vals of 12 weeks, 1 year and then annually thereafter. For individuals
with bipolar disorders, healthcare services are advised to routinely
monitor weight and other cardiovascular and metabolic indicators
of morbidity, although the frequency of monitoring is not speci-
fied.14 The Royal College of Psychiatrists15 recommend that for
people prescribed second-generation antipsychotic medication,
body mass index and/or waist circumference, blood pressure,
current and previous smoking status, lipids including low-density
lipoprotein and high-density lipoprotein (HDL) and random or
fasting glucose should all be measured.
Study aims
The continued development of large electronic record data-sets and
data science has offered both feasible and relatively inexpensive
approaches to help study real-world data and real-world evidence.16
The proliferation of electronic health records offers a number of
advantages over standard clinical trial data such as helping to quan-
tify levels of diseases such as diabetes in clinical groups that are at
high risk and difficult to access within current service structures.
Additionally, the availability of new methods of screening for disor-
ders such as using glycosylated haemoglobin in diabetes,17 may offer
an opportunity to identify and treat populations that may otherwise* These authors contributed equally to this work.
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be missed with existing approaches. Disorders such as diabetes are
more common in people with SMI, and early detection may help to
develop more effective ways of improving outcomes for this condi-
tion.18 The aim of our study was to use a novel health informatics
and data linkage approach to investigate levels of health screening,
cardiometabolic disease and adverse health outcomes in people with
SMI over a 2-year period.
Method
Data sources
We linked patient records in a retrospective cross-sectional analysis
from the Glasgow Psychosis Clinical Information System
(PsyCIS)19 to the following Scottish Morbidity Records data-
sets:20 general/acute in-patient and day case, mental health in-
patient and day case, NHS Greater Glasgow and Clyde generated
blood test results from Scottish Care Information, the
Prescriptions Information System, and National Records of
Scotland death certification records over a 2-year period to the 12
November, 2015. The PsyCIS data-set uniquely contains clinical
and sociodemographic information gathered on over 10 000
patients (patients in active treatment with NHS Greater Glasgow
and Clyde adult mental health services on 12 November 2015)
with SMI over 10 years, both community and in-patients, compris-
ing mainly diagnoses of schizophrenia and bipolar illness, but also
organic psychosis, psychotic depression and substance-induced
psychosis. The data-set includes age, gender, ICD-1021 diagnosis,
Community Health Index number, ethnicity, marital status,
accommodation status and postcode, employment status, educa-
tional attainment, family history of psychosis, psychiatric admis-
sions data, current illness severity (including Clinical Global
Impression22 and Health of the Nation Outcome Scale scores23),
current and previous medications and psychiatric comorbidities.
Data linkage
Data linkage to the Scottish Care Information store data repository
enabled us to calculate by diagnosis, gender, age group and depriv-
ation quintile the numbers of patients with no record, one, two and
three recordings, for a range of blood markers. All data were linked
over a 2-year period to the last recorded date in the PsyCis database
(7718 patients on 12 November 2015). Those patients that had died
during that period were removed from the data file prior to analysis
(Fig. 1). We identified those who had at any time during that period
had recorded an elevated glucose (≥11.1 mmol/L), elevated total
cholesterol (≥5.0 mmol/L), low HDL cholesterol (≤1.0 mmol/L
for men and ≤1.3 mmol/L for women) and an elevated HbA1c
(≥48 mmol/mol). We then linked these data to the encashed com-
munity prescriptions information system and calculated the
numbers who were prescribed any drug under British National
Formulary (BNF)24 section 3 (antidiabetic drugs) for raised
glucose and raised HbA1c, or any lipid-regulating drug under
BNF section 2.12 for raised total cholesterol and HDL cholesterol.
Socioeconomic status was measured using the postcode-based
Scottish Index of Multiple Deprivation (SIMD) by SIMD rank
and divided into quintiles.
Total number of safe haven ids
9344
No record in PsyCis file
n = 292
Total number before deaths
removed 8768
Number of participants in study
7718
Missing demographic and SIMD data
n = 284
Deaths prior to 12 November 2015
n = 1050
Number in PsyCis database
9052
Fig. 1 Flow chart of study numbers (Psychosis Clinical Information System, PsyCIS).




We used Stata version 13.1 for statistical analysis. We used descrip-
tive statistics to describe the population, such as mean values for
continuous variables; counts (n), and proportions (%) were reported
for categorical variables. Age- and gender-specific rates were gener-
ated for five age groups (16–34, 35–44, 45–54, 55–65, 65 and over).
Odds ratios (ORs) frommultivariable logistic regression were calcu-
lated with their 95%CIs to define any association between the OR of
having a raised measure (dependent variable) and its associated
factors (independent variables) gender, diagnosis, age groups and
deprivation quintile, and also the OR of being on the appropriate
medication if a raised measure had been recorded. A P<0.05 was
considered for significant difference. We used complete case ana-
lysis for missing data for all demographic and SIMD analyses.
Results
Demographic and clinical characteristics
We identified data for a total of 7718 individuals on the PsyCIS
database with complete sociodemographic and deprivation data
(Fig. 1). Patients with schizophrenia comprised 40.9% of the
cohort, bipolar disorder 24.2%, and ‘other psychotic disorders’
34.9% (Table 1). A total of 56.1% of the cohort were male and
43.9% were female (Table 1). In total, 54% of patients in the
PsyCIS cohort lived in the most deprived quintile of Glasgow com-
pared with only 8.3% who lived in the most affluent quintile (see
supplementary Table 1; available at https://doi.org/10.1192/bjo.
2019.76).
Blood monitoring
No routine blood monitoring had been conducted in 16.9% of
patients within the preceding 2 years. Individuals with ‘other psych-
otic disorders’ (19.9%, P<0.001) received the least screening fol-
lowed by patients with schizophrenia (17.0%) whereas those with
bipolar disorder received the most screening with 12.3%
(Table 1). Monitoring of routine blood markers was poorer in
male patients (18.6%) compared with females (14.6%, P<0.001)
(Table 1) and younger age groups (26.5%) were twice as likely not
to have a clinical record of routine blood monitoring than older
groups (11.6%, P<0.001). About half of those not being screened
were in the age group 16–44 years (see supplementary Table 2).
Table 1 Routine blood monitoring in the preceding 2 years, by diagnosis and gender
Total, n (%)











Male 4327 (56.1) 805 (18.6) 939 (21.7) 922 (21.3) 1661 (38.4) <0.001
Female 3391 (43.9) 496 (14.6) 682 (20.1) 750 (22.1) 1463 (43.1)
Other diagnosis 2696 (34.9) 537 (19.9) 592 (22.0) 587 (21.8) 980 (36.4) <0.001
Bipolar 1868 (24.2) 229 (12.3) 366 (19.6) 396 (21.2) 877 (47.0)
Schizophrenia 3154 (40.9) 535 (17.0) 663 (21.0) 689 (21.9) 1267 (40.2)
Cholesterol
Men 4327 (56.1) 995 (23.0) 1105 (25.5) 1050 (24.3) 1177 (27.2) 0.686
Women 3391 (43.9) 761 (22.4) 838 (24.7) 849 (25.0) 943 (27.8)
Other diagnosis 2696 (34.9) 785 (29.1) 723 (26.8) 623 (23.1) 565 (21.0) <0.001
Bipolar 1868 (24.2) 353 (18.9) 436 (23.3) 491 (26.3) 588 (31.5)
Schizophrenia 3154 (40.9) 618 (19.6) 784 (24.9) 785 (24.9) 967 (30.7)
Albumin
Men 4327 (56.1) 760 (17.6) 588 (13.6) 638 (14.7) 2341 (54.1) <0.001
Women 3391 (43.9) 449 (13.2) 380 (11.2) 499 (14.7) 2063 (60.8)
Other diagnosis 2696 (34.9) 493 (18.3) 338 (12.5) 361 (13.4) 1504 (55.8) <0.001
Bipolar 1868 (24.2) 197 (10.6) 208 (11.1) 270 (14.5) 1193 (63.9)
Schizophrenia 3154 (40.9) 519 (16.5) 422 (13.4) 506 (16.0) 1707 (54.1)
HbA1c
Men 4327 (56.1) 2951 (68.2) 600 (13.9) 274 (6.3) 502 (11.6) 0.391
Women 3391 (43.9) 2367 (69.8) 454 (13.4) 213 (6.3) 357 (10.5)
Other diagnosis 2696 (34.9) 2014 (74.7) 324 (12.0) 136 (5.0) 222 (8.2) 0.001
Bipolar 1868 (24.2) 1289 (69.0) 261 (14.0) 113 (6.1) 205 (11.0)
Schizophrenia 3154 (40.9) 2015 (63.9) 469 (14.9) 238 (7.6) 432 (13.7)
Triglycerides
Men 4327 (56.1) 998 (23.1) 1107 (25.6) 1048 (24.2) 1174 (27.1) 0.778
Women 3391 (43.9) 763 (22.5) 846 (25.0) 841 (24.8) 941 (27.8)
Other diagnosis 2696 (34.9) 785 (29.1) 727 (27.0) 624 (23.2) 560 (20.8) <0.001
Bipolar 1868 (24.2) 355 (19.0) 438 (23.5) 485 (26.0) 590 (31.6)
Schizophrenia 3154 (40.9) 621 (19.7) 788 (25.0) 780 (24.7) 965 (30.6)
Creatinine
Men 4327 (56.1) 728 (16.8) 752 (17.4) 710 (16.4) 2137 (49.4) <0.001
Women 3391 (43.9) 409 (12.1) 497 (14.7) 512 (15.1) 1973 (58.2)
Other diagnosis 2696 (34.9) 472 (17.5) 464 (17.2) 395 (14.7) 1365 (50.6) <0.001
Bipolar 1868 (24.2) 182 (9.7) 214 (11.5) 241 (12.9) 1231 (65.9)
Schizophrenia 3154 (40.9) 483 (15.3) 571 (18.1) 586 (18.6) 1514 (48.0)
ALT
Men 4327 (56.1) 766 (17.7) 822 (19.0) 762 (17.6) 1977 (45.7) <0.001
Women 3391 (43.9) 458 (13.5) 560 (16.5) 592 (17.5) 1781 (52.5)
Other diagnosis 2696 (34.9) 495 (18.4) 490 (18.2) 425 (15.8) 1286 (47.7) <0.001
Bipolar 1868 (24.2) 208 (11.1) 290 (15.5) 319 (17.1) 1051 (56.3)
Schizophrenia 3154 (40.9) 521 (16.5) 602 (19.1) 610 (19.3) 1421 (45.1)
HbA1c, haemoglobin A1c; ALT, alanine aminotransferase.
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Screening for cholesterol and triglyceride levels was poor for all
diagnostic categories with cholesterol screening being particularly
poor in ‘other psychotic conditions’ (29.1%) followed by schizo-
phrenia (19.6%) and bipolar disorders (18.9%, P<0.001).
Triglyceride screening showed a similar pattern with least screening
in ‘other psychotic conditions’ (29.1%) compared with schizophre-
nia (19.7%) and bipolar conditions (19.0%, P<0.001). Screening for
HbA1c were poorly recorded for all diagnostic groups with ‘other
psychotic conditions’ being (74.7%), bipolar disorder (69.0%) and
schizophrenia (63.9%, P = 0.001).
Abnormal blood parameters
Glucose
In total 588 patients (7.6%) of the total 7718 cohort had a record of a
raised glucose measure ≥11.1 mmol/L in the preceding 2 years of
monitoring (Table 2). Raised glucose levels ≥11.1 mmol/L were
higher in those with schizophrenia (8.8%, OR = 1.29, 95% CI
1.05–1.58, P = 0.013), compared with the ‘other psychotic disorders’
category (6.3%) and results for bipolar disorder (7.6%, OR = 1.11,
95% CI 0.88–1.41, P = 0.391). No difference was found by gender
but the proportion of patients with a raised glucose increased mark-
edly with age. Raised glucose levels ≥11.1 mmol/L were highest in
the oldest age groups (age 65 and over, 10.7%, OR = 4.22, 95% CI
2.77–6.42, P<0.001) (Table 2) compared with the youngest group
(age 16–34, 2.7%) with levels similar to the general population.25
Of the total 588 patients with a raised glucose, 382 (65.0%) were
on medication for diabetes (see supplementary Table 3).
Glycosylated haemoglobin
In total, 754 patients (9.8%) had a record of an elevated glycosylated
haemoglobin (HbA1c), indicating underlying or poorly controlled
diabetes (Table 2). Raised HbA1c (≥48 mmol/mol) was greater in
those patients with schizophrenia (11.5%, OR = 1.40, 95% CI
1.16–1.68, P<0.001) compared with ‘other psychotic disorders’
(7.7%), and for bipolar disorder (9.8%, OR = 1.16, 95% CI 0.94–
1.44, P = 0.168) (Table 2). Levels of elevated HbA1c increased mark-
edly with age with the highest in those aged 65 and above (15.8%,
OR = 5.82, 95% CI 3.95–8.56, P<0.001) and only for deprivation
quintile 4 (10.9%, OR = 1.47, 95% CI 1.04–2.07, P = 0.028). Of the
754 with an elevated HbA1c, 572 (75.9%, 7.4% of total cohort)
were on medication for diabetes (see supplementary Table 3).
Prevalence of diabetes mellitus
Overall for this sample of patients, the prevalence of diabetes iden-
tifiable by this methodology was approximately 8.0%. In total
588 patients (7.6% of total cohort) had an elevated glucose
(≥11.1 mmol/L) and of these 382 (65.0%) were on medication for
diabetes. An elevated glycosylated haemoglobin was found in 754
patients (9.8%) and of these 572 (75.9%) were on medication,
levels of treatment similar to the general population.25
Total cholesterol/HDL cholesterol
Overall 3717 patients (48.2%) had a record of elevated cholesterol
levels ≥5.0 mmol/L) (Table 2). An elevated cholesterol (≥5 mmol/L)
was higher in those with bipolar disorder (53.3%, OR = 1.36, 95%
CI 1.20–1.54, P<0.001), compared with ‘other psychotic disorders’
category (42.7%) and an elevated cholesterol was found in those
with schizophrenia (49.8%, OR = 1.30, 95% CI 1.17–1.45, P<0.001),
compared with ‘other psychotic disorders’ category (42.7%). Of
the total number 23.9% were on lipid-regulating medication (see
supplementary Table 3).
In total 2821 (36.6%) patients were found to have a low HDL
cholesterol level (Table 2). More patients were found to have a
low HDL cholesterol level with bipolar disorder (40.5%, OR =
1.38, 95% CI 1.21–1.56, P<0.001) compared with ‘other psychotic
disorders’ category (31.0%), while 38.9% of patients with schizo-
phrenia (OR = 1.43, 95% CI 1.28–1.60, P<0.001) were found to
have a low HDL cholesterol level. Of these 1060 (37.6%) patients
were on lipid-lowering medication.
Discussion
This comprehensive data linkage study addresses a key knowledge
gap in the monitoring and treatment of physical health problems
in patients with SMI. The principal findings are that routine screen-
ing has improved in recent years, with only 16.9% of the cohort
having no record of routine blood monitoring within the preceding
2 years. The most recent screening studies by Crawford et al12
(2011) found that only 59.8% of patients had a plasma glucose
recorded and Barnes et al11 in 2006 found with only 28.0% of
patients had received blood monitoring. However, overall monitor-
ing was poorer for male patients, people with schizophrenia and for
younger SMI patients (16–44) where 23.9% of individuals had no
record of screening. In all age groups, blood monitoring for lipids
and glycosylated haemoglobin was poor, especially for those aged
16–44.
In total 7.6% of the cohort had an elevated plasma glucose
recorded within the last 2 years and 9.8% had a raised HbA1c
with both of these indices were notably raised in schizophrenia
and older patients. Levels of diabetes identifiable by this method-
ology were approaching twice that for the general population.25
We found that lipid levels and use of lipid-lowering medication
were generally high in our study. In total 48.2% of the cohort
(bipolar disorder 53.3%) were found to have a record of a cholesterol
level over the recommended level of 5.0 mmol/L, and 36.6% of the
total (bipolar disorder 40.5%) with a HDL cholesterol≤1.0 mmol/L.
In the general population in Scotland, 51.9% of people were found to
have a cholesterol level≥5.0 mmol/L and 10.8% an HDL cholesterol
≤1.0 mmol/L.26 In our study 23.9% of people with a cholesterol
≥5.0 mmol/L were on lipid-lowering medication and 37.6% with
a HDL cholesterol ≤1.0 mmol/L, compared with treatment levels
of about 15% in the general population.26
Strengths and limitations
The strength of our study is the use of novel health informatics to
monitor the health outcomes of 7718 people with SMI. Electronic
record linkage allowed the analysis of near real-time clinical and
prescribing data alongside access to a large clinical population
that can be difficult to reach by standard approaches. Recent devel-
opments allowing screening for diabetes using glycosylated haemo-
globin27 proved important in helping to identify levels of morbidity
in this population, although some problems exist with this method
when used in specific populations.27 Limitations of this study
include our inability to investigate the role of other associated risk
factors for physical comorbidity such as weight problems,
smoking, dietary intake or sedentary behaviour. We also recognise
that a (very small) proportion of patients may have received
blood sampling or treatment elsewhere. We did not have access to
a suitable control group within the database. Therefore our findings
were compared with results found in the general population rather
than an equivalent comparison group particularly in NHS Glasgow
and Clyde where additional significant health problems are recog-
nised. Additionally, some patients with significant levels of mental
illness may not have attended any health services and therefore









n (%) ORa (95% CI) OR P
Raised cholesterol
(≥5.0 mmol/L), n (%) ORa (95% CI) OR P
Reduced HDL
cholesterol (≤1.0b
mmol/L), n (%) ORa (95% CI) OR P
Raised HbA1c
(≥48.0 mmol/mol),
n (%) ORa (95% CI) OR P
Total 7718 588 (7.6) 3717 (48.2) 2821 (36.6) 754 (9.8)
Gender
Women 3391 253 (7.5) Ref. (1.00) 1743 (51.4) 1.00 1407 (41.5) 1.00 320 (9.4) 1.00
Men 4327 335 (7.7) 1.10 (0.93–1.32) 0.271 1974 (45.6) 0.83 (0.76–0.92) <0.001 1414 (32.7) 0.69 (0.63–0.76) <0.001 434 (10.0) 1.17 (1.00–1.37) 0.057
Diagnosis
Other diagnoses 2696 170 (6.3) 1.00 1151 (42.7) 1.00 836 (31.0) 1.00 207 (7.7) 1.00
Bipolar 1868 141 (7.6) 1.11 (0.88–1.41) 0.391 996 (53.3) 1.36 (1.20–1.54) <0.001 757 (40.5) 1.38 (1.21–1.56) <0.001 183 (9.8) 1.16 (0.94–1.44) 0.168
Schizophrenia 3154 277 (8.8) 1.29 (1.05–1.58) 0.013 1570 (49.8) 1.30 (1.17–1.45) <0.001 1228 (38.9) 1.43 (1.28–1.60) <0.001 364 (11.5) 1.40 (1.16–1.68) <0.001
Age group
16–34 1139 31 (2.7) 1.00 383 (33.6) 1.00 294 (25.8) 1.00 35 (3.1) 1.00
35–44 1611 87 (5.4) 1.96 (1.29–2.98) 0.002 735 (45.6) 1.60 (1.37–1.88) <0.001 531 (33.0) 1.33 (1.12–1.58) 0.001 91 (5.7) 1.80 (1.21–2.68) 0.004
45–54 2348 190 (8.1) 3.03 (2.05–4.46) <0.001 1293 (55.1) 2.35 (2.03–2.73) <0.001 938 (40.0) 1.76 (1.50–2.06) <0.001 234 (10.0) 3.34 (2.32–4.81) <0.001
55–64 1757 188 (10.7) 4.18 (2.83–6.18) <0.001 929 (52.9) 2.08 (1.78–2.44) <0.001 733 (41.7) 1.83 (1.55–2.16) <0.001 258 (14.7) 5.30 (3.68–7.62) <0.001
65 and over 863 92 (10.7) 4.22 (2.77–6.42) <0.001 377 (43.7) 1.39 (1.15–1.67) 0.001 325 (37.7) 1.51 (1.25–1.84) <0.001 136 (15.8) 5.82 (3.95–8.56) <0.001
Deprivation quintile
Least deprived 643 42 (6.5) 1.00 349 (54.3) 1.00 226 (35.2) 1.00 48 (7.5) 1.00
2 634 33 (5.2) 0.77 (0.48–1.24) 0.287 341 (53.8) 0.97 (0.77–1.21) 0.777 228 (36.0) 1.03 (0.82–1.30) 0.796 52 (8.2) 1.09 (0.72–1.65) 0.672
3 901 73 (8.1) 1.23 (0.83–1.84) 0.298 463 (51.4) 0.85 (0.69–1.05) 0.128 310 (34.4) 0.95 (0.77–1.18) 0.649 90 (10.0) 1.36 (0.94–1.97) 0.106
4 1398 113 (8.1) 1.21 (0.84–1.76) 0.309 674 (48.2) 0.77 (0.64–0.93) 0.007 501 (35.8) 1.04 (0.85–1.27) 0.708 153 (10.9) 1.47 (1.04–2.07) 0.028
Most deprived 4142 327 (7.9) 1.17 (0.83–1.64) 0.367 1890 (45.6) 0.69 (0.58–0.81) <0.001 1556 (37.6) 1.13 (0.94–1.35) 0.187 411 (9.9) 1.30 (0.95–1.79) 0.104
a. Odds ratios adjusted for all other variables.










We estimated the prevalence of diabetes using a range of markers
such as glycosylated haemoglobin levels and a single random blood
glucose level rather than conventional investigations such as a stand-
ard fasting glucose level, 2 h post-prandial test, or two or more raised
random plasma glucose levels (≥11.1 mmol/L).28 Although we
looked at the last 2 years of records, we may have missed individuals
who have been diagnosed with diabetes or hypercholesterolemia,
received successful treatment and had plasma glucose or cholesterol
levels below the threshold for detection by our method. Our figures
for the prevalence of diabetes and hypercholesterolemia are therefore
likely to be an underestimate of actual comorbidity. A recent system-
atic review found the estimated overall worldwide pooled prevalence
of diabetes in people with SMI to be 11.3%.29 However studies in this
systematic review, using only similar cross-sectional methods, found
the pooled prevalence to be 9.2%, and within the geographical area of
Europe to be 7.7%, compared with 8.0% in our study.
We found that people with bipolar disorder received better
levels of care than those with schizophrenia. The reasons for this
were not clear, although some patients with bipolar disorder may
receive regular health monitoring for routine medication, such as
therapeutic plasma levels of lithium therapy. These findings may
also be specific to our study, or reflect the wide variation in clinical
care found in patients with SMI.29
Implications
We have demonstrated that a novel approach using health inform-
atics and linkage of routine clinical data (in an urban clinical popu-
lation in Scotland) has considerable potential to assist in the
improvement of physical health outcomes for people with SMI. It
can establish baseline practice at a system-wide level (in our case
a complete health board delivering care to around 21% of the
Scottish population) and help determine the type of quality
improvement needed across the National Health Service (NHS) in
order to deliver better identification, monitoring and treatment of
comorbid physical illness for individuals with SMI. Our research
is a first step towards using health informatics to establish exactly
how well NHS services in their totality are performing against a
set of predetermined clinical tasks, within a specified group of
patients in need. If reproduced across the rest of the UK, this
could form the basis against which the implementation of a
complex intervention aimed at improving the physical health of
people with SMI could be measured. Although we did not
conduct a health economic analysis, the use of routine data in this
way has the potential to be more cost-effective than large-scale clin-
ical audits.
In summary, this comprehensive data linkage study supports
the use of health informatics as a means for improving physical
health outcomes in patients with SMI. It has highlighted a
number of important implications for clinical practice, most
notably that we will continue to miss screening for a substantial pro-
portion of patients unless we make system-level changes. Future
work should be more ambitious and should replicate this approach
across the UK, for example, to identify regional variations in prac-
tice and local variations in numbers of patients with these needs, so
that resources can be more efficiently targeted to help mitigate
health inequalities.
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